<DOC>
	<DOCNO>NCT01375322</DOCNO>
	<brief_summary>The purpose study compare change baseline blood pressure ( DBP/SBP ) 16-week regimen Amtrel® Co-Diovan® . The secondary objective list follow . - To compare response rate ( define SBP &lt; 130 mmHg DBP &lt; 80 mmHg ) end study - To evaluate change baseline albumin-to-creatinine ratio antihypertensive medication whole group ( combine treatment group ) treatment group ( Amtrel® , Co-Diovan® ) Week 16 - The change baseline glycosylated hemoglobin ( HbA1c ) Week 16 - The change baseline fast plasma glucose ( FPG ) Week 16 - The change baseline fast lipid profile ( triglyceride , total cholesterol , high-density lipoprotein cholesterol , low-density lipoprotein cholesterol ) Week 16 - The change baseline arteriosclerosis marker ( brachial-ankle pulse-wave velocity ( ba-PWV ) ankle-brachial pressure index ( ABI ) , use Colin-VP1000 ) Week 16 - The change baseline body mass index ( BMI ) waist-hip ratio ( WHR ) specify study time point - To ascertain safety tolerability Amtrel® versus Co-Diovan® include AE/SAE , laboratory examination</brief_summary>
	<brief_title>ADDM Study - Amtrel Co-Diovan Type 2 Diabetes Mellitus Hypertension Patients With Microalbuminuria</brief_title>
	<detailed_description>At screen visit , patient fulfil entrance criterion give write informed consent enter placebo running period discontinue antihypertensive medication two week . During period , Adalat 5mg could give emergency . At end placebo run period patient become hypertensive ( i.e. , SBP 130-180mmHg DBP 80-110mmHg ) randomize either treatment group . For patient remain normotensive continue placebo run-in another two week ( 10 - 14 day ) . After two-week ( 10 - 14 day ) placebo run-in period patient become hypertensive randomize either treatment group . However patient remain normotensive exclude study . After randomization either arm , patient enter four month treatment period . The dosage adjustment proceed order reach best effect . During treatment period monthly visit ass response patient . The start dose Amtrel® 1 capsule ( contain 1/2 tablet ) ( amlodipine / benazepril hydrochloride 2.5 mg/ 5 mg ) every morning could adjust 2 capsule ( contain 1 tablet per capsule ) ( amlodipine / benazepril hydrochloride 10 mg/ 20 mg ) every morning patient achieve criterion SBP &lt; 130 mmHg DBP &lt; 80 mmHg treatment period . The start dose Co-Diovan® 1 capsule ( contain 1/2 tablet ) ( valsartan/ hydrochlorothiazide 40 mg/ 6.25 mg ) every morning could adjust 2 capsule ( contain 1 tablet per capsule ) ( valsartan/ hydrochlorothiazide 160 mg/ 25.0 mg ) every morning patient achieve criterion SBP &lt; 130 mmHg DBP &lt; 80 mmHg treatment period . All randomized patient attend monthly clinic visit 16-week treatment period . At week 4 ( Visit 3 ) , patient force-titrated 1 capsule ( 1 tablet per capsule ) 4 week . Subsequently , patient achieve target blood pressure ( SBP &lt; 130 mmHg DBP &lt; 80 mmHg ) titrate monthly next dose level ( 2 capsule per day ) .</detailed_description>
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Hypertension</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Albuminuria</mesh_term>
	<mesh_term>Benazepril</mesh_term>
	<mesh_term>Valsartan</mesh_term>
	<mesh_term>Hydrochlorothiazide</mesh_term>
	<mesh_term>Amlodipine</mesh_term>
	<criteria>type 2 diabetes stable control ( HbA1c 6.510 % ) SBP 130180mmHg DBP 80110mmHg microalbuminuria ( UAE 30300mg/24hrs creatinine 30300mg/g ) IDDM secondary form diabetes hepatic and/or renal dysfunction serum potassium level &gt; 5.5mmol/L severe renal disease Chronic Heart Failure ( NYHA class III IV ) unstable CV disease PTCA within 3 month</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>June 2011</verification_date>
</DOC>